{"id":870888,"date":"2025-08-05T08:54:58","date_gmt":"2025-08-05T12:54:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\/"},"modified":"2025-08-05T08:54:58","modified_gmt":"2025-08-05T12:54:58","slug":"microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\/","title":{"rendered":"Microbot Medical\u00ae Receives Non-Dilutive Grant to Enhance Operational Capabilities"},"content":{"rendered":"<h2>\nStrengthens Balance Sheet and Continues Commercialization Readiness Plans for the LIBERTY\u00ae System as it Nears FDA Marketing Clearance Decision<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">HINGHAM, Mass., Aug.  05, 2025  (GLOBE NEWSWIRE) &#8212; Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY<sup>\u00ae<\/sup> Endovascular Robotic System, announced it has been approved to receive a non-dilutive grant from the Israel Innovation Authority (&#8220;IIA\u201d) in the amount of NIS 2.15 Million (approximately $630,000 at a recent exchange rate). The funding will further strengthen the Company\u2019s manufacturing capabilities, positioning it to successfully implement the commercialization of the LIBERTY<sup>\u00ae<\/sup> System, pending marketing clearance by the U.S. Food and Drug Administration (FDA).<\/p>\n<p align=\"justify\">In addition to recognizing the Company\u2019s recent milestone achievements, the IIA acknowledged several other factors in its final decision, including the size and characteristics of the target market, the competitive advantages of a single-use, disposable robot, the regulatory status of the LIBERTY<sup>\u00ae<\/sup> System and the overall benefits it is expected to deliver to the end user and healthcare system. The Company believes that the grant validates its technology and reflects the rigorous, independent due diligence conducted by the IIA.<\/p>\n<p align=\"justify\">\u201cThis non-dilutive grant strengthens our balance sheet and allows us to further enhance our operational readiness plans as we await the FDA\u2019s marketing clearance decision,\u201d commented Rachel Vaknin, Chief Financial Officer. \u201cThe IIA has been a valued partner supporting the development of the LIBERTY<sup>\u00ae<\/sup> System with prior grants, and this latest award and timing is particularly significant as we believe it reflects high confidence in our ability to scale manufacturing and successfully meet our business objectives.\u201d<\/p>\n<p align=\"justify\">LIBERTY<sup>\u00ae<\/sup>\u00a0is an investigational device pending FDA 510(k) clearance, and is currently not available for sale in the\u00a0U.S.<\/p>\n<p align=\"justify\">\n        <strong>About Microbot Medical<\/strong>\n      <\/p>\n<p align=\"justify\">Microbot Medical Inc.\u00a0(NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to redefine endovascular robotics and improve the quality of care for millions of patients and providers globally. The Company has developed the world\u2019s first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems.<\/p>\n<p>Further information about Microbot Medical<sup>\u00ae<\/sup> is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nDQnInPL-uA8oRzOIUkc8tU3KvB0B1C1YavCH6xjrWcTISZ4CExSePulaoXuHYL0V0IvAhNWe3zxMcVpLz70Ub9fE25cWzx8VaLduAdl0dixKzx9Q1f1z1iC4vdM_qClpwv7h2F5UsNvQYPMG6GuEb_Umwn0fNBDdORnZzYrbEt_IXLfdFQ_-n4uU_r8NYz1B6-XZGtGTt4oQnVQCRKx4Q==\" rel=\"nofollow\" target=\"_blank\">http:\/\/www.microbotmedical.com<\/a>.<\/p>\n<p>\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">Statements to future financial and\/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as \u201ccontemplates,\u201d \u201ccontinues,\u201d \u201ccould,\u201d \u201cforecasts,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredicts,\u201d \u201cprojects,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cwill,\u201d \u201cbelieves,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cestimates\u201d and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company\u2019s need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and\/or commercialization of the LIBERTY Endovascular Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will timely grant 510(k) clearance to commercially market the LIBERTY Endovascular Robotic System in the United States if at all, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical<sup>\u00ae<\/sup> can be found under the heading \u201cRisk Factors\u201d in Microbot Medical\u2019s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC\u2019s web site at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Tez1rbgBPG7K8yqI3Z0SPwYFrepMiiAIFyxVdcoQ5XCjVJ7d-RcUTWj_nb55Y6wYJRQFfm1lw29wWT3rQzieM8nxPuVDAqY0Ns5ZNydG_hYOycvJ43vGchYifCwZC0dEy8ZIq8Cay9kahNe2-Y0NMa29KCszjuKl2ZnIBGBBwvY=\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a>. Microbot Medical<sup>\u00ae<\/sup> disclaims any intent or obligation to update these forward-looking statements, except as required by law.<\/p>\n<p>\n        <strong>Investor Contact: <\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d88_mNwi9YUpWppegYLimf9CFACK3TJcK_bItl4EdFuHs8doazJ_PfoKSv_HAJeLrGbFCMY1tjlZhng9ISRsKjdlkbUtEyU3xL6c3W7GreE=\" rel=\"nofollow\" target=\"_blank\">IR@microbotmedical.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNjE2OCM3MDgxNjg5IzIwODI0OTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTAxNjg2OWQtMDFjMy00ZDVhLWFkMmYtNWU1NjE2YjU4MWRlLTEwOTQwNjgtMjAyNS0wOC0wNS1lbg==\/tiny\/Microbot-Medical-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Strengthens Balance Sheet and Continues Commercialization Readiness Plans for the LIBERTY\u00ae System as it Nears FDA Marketing Clearance Decision HINGHAM, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) &#8212; Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY\u00ae Endovascular Robotic System, announced it has been approved to receive a non-dilutive grant from the Israel Innovation Authority (&#8220;IIA\u201d) in the amount of NIS 2.15 Million (approximately $630,000 at a recent exchange rate). The funding will further strengthen the Company\u2019s manufacturing capabilities, positioning it to successfully implement the commercialization of the LIBERTY\u00ae System, pending marketing clearance by the U.S. Food and Drug Administration (FDA). In addition to recognizing the Company\u2019s recent milestone achievements, the IIA acknowledged several other factors in its final decision, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Microbot Medical\u00ae Receives Non-Dilutive Grant to Enhance Operational Capabilities&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-870888","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Microbot Medical\u00ae Receives Non-Dilutive Grant to Enhance Operational Capabilities - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Microbot Medical\u00ae Receives Non-Dilutive Grant to Enhance Operational Capabilities - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Strengthens Balance Sheet and Continues Commercialization Readiness Plans for the LIBERTY\u00ae System as it Nears FDA Marketing Clearance Decision HINGHAM, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) &#8212; Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY\u00ae Endovascular Robotic System, announced it has been approved to receive a non-dilutive grant from the Israel Innovation Authority (&#8220;IIA\u201d) in the amount of NIS 2.15 Million (approximately $630,000 at a recent exchange rate). The funding will further strengthen the Company\u2019s manufacturing capabilities, positioning it to successfully implement the commercialization of the LIBERTY\u00ae System, pending marketing clearance by the U.S. Food and Drug Administration (FDA). In addition to recognizing the Company\u2019s recent milestone achievements, the IIA acknowledged several other factors in its final decision, &hellip; Continue reading &quot;Microbot Medical\u00ae Receives Non-Dilutive Grant to Enhance Operational Capabilities&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-05T12:54:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNjE2OCM3MDgxNjg5IzIwODI0OTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Microbot Medical\u00ae Receives Non-Dilutive Grant to Enhance Operational Capabilities\",\"datePublished\":\"2025-08-05T12:54:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\\\/\"},\"wordCount\":680,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNjE2OCM3MDgxNjg5IzIwODI0OTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\\\/\",\"name\":\"Microbot Medical\u00ae Receives Non-Dilutive Grant to Enhance Operational Capabilities - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNjE2OCM3MDgxNjg5IzIwODI0OTc=\",\"datePublished\":\"2025-08-05T12:54:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNjE2OCM3MDgxNjg5IzIwODI0OTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNjE2OCM3MDgxNjg5IzIwODI0OTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Microbot Medical\u00ae Receives Non-Dilutive Grant to Enhance Operational Capabilities\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Microbot Medical\u00ae Receives Non-Dilutive Grant to Enhance Operational Capabilities - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\/","og_locale":"en_US","og_type":"article","og_title":"Microbot Medical\u00ae Receives Non-Dilutive Grant to Enhance Operational Capabilities - Market Newsdesk","og_description":"Strengthens Balance Sheet and Continues Commercialization Readiness Plans for the LIBERTY\u00ae System as it Nears FDA Marketing Clearance Decision HINGHAM, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) &#8212; Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY\u00ae Endovascular Robotic System, announced it has been approved to receive a non-dilutive grant from the Israel Innovation Authority (&#8220;IIA\u201d) in the amount of NIS 2.15 Million (approximately $630,000 at a recent exchange rate). The funding will further strengthen the Company\u2019s manufacturing capabilities, positioning it to successfully implement the commercialization of the LIBERTY\u00ae System, pending marketing clearance by the U.S. Food and Drug Administration (FDA). In addition to recognizing the Company\u2019s recent milestone achievements, the IIA acknowledged several other factors in its final decision, &hellip; Continue reading \"Microbot Medical\u00ae Receives Non-Dilutive Grant to Enhance Operational Capabilities\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-05T12:54:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNjE2OCM3MDgxNjg5IzIwODI0OTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Microbot Medical\u00ae Receives Non-Dilutive Grant to Enhance Operational Capabilities","datePublished":"2025-08-05T12:54:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\/"},"wordCount":680,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNjE2OCM3MDgxNjg5IzIwODI0OTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\/","name":"Microbot Medical\u00ae Receives Non-Dilutive Grant to Enhance Operational Capabilities - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNjE2OCM3MDgxNjg5IzIwODI0OTc=","datePublished":"2025-08-05T12:54:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNjE2OCM3MDgxNjg5IzIwODI0OTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNjE2OCM3MDgxNjg5IzIwODI0OTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Microbot Medical\u00ae Receives Non-Dilutive Grant to Enhance Operational Capabilities"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/870888","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=870888"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/870888\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=870888"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=870888"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=870888"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}